Interim Results With Genta's Lymphoma Drug

23 June 1996

Genta has announced that its antisense drug G3139 shows high tolerance with no dose-related toxicities, according to interim results released from its Phase I/IIa dose-ranging trial in non-Hodgkins lymphoma patients. The data were scheduled for presentation last week at the International Conference on Malignant Lymphoma in Switzerland.

The "anticode" drug, administered subcutaneously for 14 days, targets the BCL2 gene involved in the development of lymphoma. G3139 binds to the mRNA of the BCL2 gene, diminishing production of its mutant protein. Approximately half of the nine patients enrolled saw reductions or elimination of tumors or other disease symptoms, with one potential side effect being reversible topical irritation. The trial will continue until the maximum tolerated dose is established.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >

Today's issue

Company Spotlight

Ironwood is a US-based biotech advancing a pipeline of medicines in multiple areas of significant unmet need, including irritable bowel syndrome with constipation ((IBS-C)/chronic idiopathic constipation (CIC), vascular and fibrotic diseases, and refractory gastroesophageal reflux disease, among others.